Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MedImmune -- Ignore unavailable to you. Want to Upgrade?

To: AJAG who wrote (153)	3/5/1999 2:48:00 PM
From: AJAG	Respond to of 416

Sorry- The news item has been corrected. The target price was raised from 60 to 70.

To: AJAG who wrote (153)	3/23/1999 2:21:00 PM
From: FFNEODOC	Read Replies (1) \| Respond to of 416

Post from a Neonatologist: We are closing in on the end of the first season for the FDA approved use of Synagis in preemies, and I suspect it will be a very successful 1 for MEDI.(Cost ~ $800/100mg vial & some babies with chronic lung disease (BPD) use several vials for each monthly dose @ 15 mg/kg/month.) This will be a sustained source of revenue since even natural infection with RSV doesn't confer immunity for too long and it's unlikely that a vaccine will be developed. The same technology used to develop this monoclonal RSV antibody will probably be helpful to treat a whole host of infectious diseases. (currently being used by MEDI to treat CMV & being developed to treat Lyme Disease.)